News Novartis preps key early breast cancer filing for Kisqali NATALEE trial readout sets up Kisqali as rival to Lilly's Verzenio as adjuvant treatment.
News FDA eyes shake-up of swift approval pathway in cancer Regulator wants more use of randomised controlled trials rather than open-label studies.
News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
News Astellas GLOWing as Claudin drug aces gastric cancer trial Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.
News Merck suffers a setback in its TIGIT programme Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.
News Servier’s $1.8bn Agios deal delivers glioma prospect IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
